2-(2-吡啶基)噻唑 | 2433-17-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(2-吡啶基)噻唑
• 中文别名: 2-(2-吡啶)噻唑
• 英文名称: 2-(pyridin-2-yl)thiazole
• 英文别名: 2-(2'-pyridyl)thiazole；2--thiazol；2-(2-Pyridyl)thiazole；2-pyridin-2-yl-1,3-thiazole
• CAS: 2433-17-2
• 化学式: C₈H₆N₂S
• 分子量: 162.215
• InChiKey: FZSXKNJOKINZSF-UHFFFAOYSA-N

物化性质

• 熔点：
  46-46.3 °C
• 沸点：
  137-139 °C(Press: 5 Torr)
• 密度：
  1.241±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-(2-吡啶基)噻唑 、 [RuCl2(hexamethylbenzene)]2 以 二氯甲烷 为溶剂， 以89%的产率得到[(η6-C6Me6)Ru(2-(pyridine-2-yl)thiazole)Cl]Cl
  参考文献：
  名称：

  Anticancer activity of new organo-ruthenium, rhodium and iridium complexes containing the 2-(pyridine-2-yl)thiazole N,N-chelating ligand

  摘要：

  The dinuclear dichloro complexes [(eta(6)-arene)(2)Ru-2(mu-Cl)(2)Cl-2] and [(eta(5)-C5Me5)(2)M-2(mu-Cl)(2)Cl-2] react with 2-(pyridine-2-yl)thiazole (pyTz) to afford the cationic complexes [(eta(6)-arene)Ru(pyTz)Cl](+) (arene = C6H6 1, p-(PrC6H4Me)-Pr-i 2 or C6Me6 3) and [(eta(5)-C5Me5)M(pyTz)Cl](+) (M = Rh 4 or Ir 5), isolated as the chloride salts. The reaction of 2 and 3 with SnCl2 leads to the dinuclear heterometallic trichlorostannyl derivatives [(eta(6)-p-(PrC6H4Me)-Pr-i)Ru(pyTz)(SnCl3)](+) (6) and [(eta(6)-C6Me6)Ru(pyTz)(SnCl3)](+) (7), respectively, also isolated as the chloride salts. The molecular structures of 4, 5 and 7 have been established by single-crystal X-ray structure analyses of the corresponding hexafluorophosphate salts. The in vitro anticancer activities of the metal complexes on human ovarian cancer cell lines A2780 and A2780cisR (cisplatin-resistant), as well as their interactions with plasmid DNA and the model protein ubiquitin, have been investigated. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2010.01.020
• 作为产物：
  描述：

  2-(pyridine-2-yl)-4,5-dihydro-1,3-thiazole 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 以90%的产率得到2-(2-吡啶基)噻唑
  参考文献：
  名称：

  DDQ诱导杂环的脱氢对C ？C双键形成：2-噻唑和2-恶唑的合成

  摘要：

  像牛一样强： 2-噻唑和2-恶唑是通过2-噻唑啉和2-恶唑啉的氧化反应形成的，不需要在C4和C5位置处有取代基。DDQ在此转化过程中起氧化剂的作用，并且不需要金属。该通用步骤显示出良好的官能团耐受性，并以中等至极好的收率提供了各种2-噻唑和2-恶唑。

  DOI：

  10.1002/asia.201300267

文献信息

• [EN] IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES<br/>[FR] IMIDAZOPYRROLOPYRIDINE EN TANT QU'INHIBITEURS DE LA FAMILLE JAK DE KINASES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018112382A1

  公开（公告）日：2018-06-21

  2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.

  2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗由JAK介导的疾病状态、紊乱和疾病，如炎症性肠病的方法。
• Selective inhibitors of rock protein kinase and uses thereof
  申请人：Green Jeremy

  公开号：US20070270386A1

  公开（公告）日：2007-11-22

  Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.

  本文描述了作为ROCK抑制剂有用的化合物。这些化合物及其药学上可接受的组合物对于治疗或减轻各种疾病的严重程度是有用的，包括心血管、炎症、神经系统或增殖性疾病或疾病。
• [EN] INSECTICIDALLY ACTIVE PYRIDYL-THIAZOLE AND PYRIDYL-THIADIAZOLE DERIVATIVES<br/>[FR] PYRIDYL-THIAZOLE ACTIF À TITRE D'INSECTICIDE ET SES DÉRIVÉS
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2013000931A1

  公开（公告）日：2013-01-03

  Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as insecticides and can be prepared in a manner known per se.

  式(I)的化合物，其中取代基如权利要求1所定义，并且式(I)的化合物的农药可接受的盐以及所有立体异构体和互变异构形式可用作杀虫剂，并且可以按照已知的方法制备。
• [EN] NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTICANCÉREUX CONTENANT DE L'IRIDIUM/RHODIUM
  申请人：UNIV WARWICK

  公开号：WO2011148124A1

  公开（公告）日：2011-12-01

  The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.

  本发明涉及用作细胞毒性物质，如抗癌药物的新型含铱和/或铑配合物，还提供了一种制备所述化合物的方法。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson H. John

  公开号：US20070105866A1

  公开（公告）日：2007-05-10

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本发明描述了调节5-脂氧合酶激活蛋白(FLAP)活性的化合物和含有该化合物的药物组合物。本发明还描述了单独使用和与其他化合物联合使用FLAP调节剂，用于治疗呼吸系统、心血管系统和其他白三烯依赖性或白三烯介导的状况或疾病。